Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 7/20 | 1.00 |
| ▸ | MGLL | Q99685 | 6/20 | 0.68 |
| ▸ | FAAH | O00519 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.68 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8779419 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL7785894 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL43882 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL43969 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL8779453 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL24939859 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL6934781 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL3291535 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL6940132 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL8779402 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118420598-A | PSMA targeting small molecular probe, radionuclide-labeled PSMA targeting small molecular probe, and preparation methods and applications thereof | 苏州大学 | 2024-08-02 | — | — | CN | claimed |
| CN-110498993-B | Porous PVA/cellulose nanocrystalline hydrogel and preparation method thereof | 芜湖万隆新材料有限公司 | 2020-05-19 | — | — | CN | claimed |
| CN-110498993-A | A kind of porous PVA/Cellulose nanocrystal hydrogel and preparation method thereof | CHANGCHUN INST APPLIED CHEMISTRY CAS | 2019-11-26 | — | — | CN | claimed |
| CN-110028781-A | A kind of selfreparing aqueous polyurethane/Cellulose nanocrystal composite material and preparation method | 中国科学院长春应用化学研究所 | 2019-07-19 | — | — | CN | claimed |
| US-12408914-B2 | Systems and methods for customizing mechanical strength in stimuli-responsive bioabsorbable materials | CILAG GMBH INTERNATIONAL (CH) | 2025-09-09 | — | — | US | disclosed |
| EP-4543502-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | Cilag GmbH International (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20240423617-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | CILAG GMBH INTERNATIONAL (CH) | 2024-12-26 | — | — | US | disclosed |
| WO-2024261659-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | CILAG GMBH INTERNATIONAL (CH) | 2024-12-26 | — | — | WO | disclosed |
| EP-4447944-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES | THE PENN STATE RESEARCH FOUNDATION (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118420598-A | PSMA targeting small molecular probe, radionuclide-labeled PSMA targeting small molecular probe, and preparation methods and applications thereof | 苏州大学 | 2024-08-02 | — | — | CN | disclosed |
| US-20240173421-A1 | MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | SEAGEN INC. | 2024-05-30 | — | — | US | disclosed |
| EP-4326333-A1 | MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | Seagen Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20090021894-A1 | CONDUCTIVE POLYMER SOLUTION, CONDUCTIVE COATING, CONDENSER AND PROCESS FOR MANUFACTURING CONDENSER | SHIN-ETSU POLYMER CO., LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1993113-A1 | CAPACITOR AND METHOD FOR FABRICATING THE CAPACITOR | SHIN-ETSU POLYMER CO., LTD. (JP) | 2008-11-19 | — | — | EP | disclosed |
| EP-1988128-A1 | CONDUCTIVE POLYMER SOLUTION, CONDUCTIVE COATING, CAPACITOR AND PROCESS FOR MANUFACTURING CAPACITOR | SHIN-ETSU POLYMER CO., LTD. (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1947655-A1 | TRANSPARENT CONDUCTIVE SHEET FOR TOUCH PANEL, METHOD FOR MANUFACTURING SAME AND TOUCH PANEL | SHIN-ETSU POLYMER CO., LTD. (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7132295-B2 | Isotopically coded affinity markers 3 | BAYER AKTIENGESELLSCHAFT (DE) | 2006-11-07 | — | — | US | disclosed |
| US-20050049406-A1 | Isotopically coded affinity markers 3 | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-03 | — | — | US | disclosed |
| EP-1446665-A2 | ISOTOPICALLY CODED AFFINITY MARKERS 3 | Bayer HealthCare AG (DE) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003040288-A2 | ISOTOPICALLY CODED AFFINITY MARKERS 3 | BAYER HEALTHCARE AG (DE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049406-A1 | Isotopically coded affinity markers 3 | IGFBP3, FABP3, LGALS3BP | PTGS1 4677/4885PTGS2 4648/4885MGLL 4839/4885 |
| US-20240173421-A1 | MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | CD47, CD2, SSB | PTGS1 3931/4885PTGS2 4054/4885MGLL 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.